Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01469793 · ClinicalTrials.gov registry record · Phase 1
A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer
A Phase 1 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 1
- Development phase
- 71
- Enrollment target
NCT01469793 is a Phase 1 study that has completed, run by Genentech. The registered enrollment target is 71 participants.
The verdict
NCT01469793, a Phase 1 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 71 participants
- Enrollment target
Study Summary
This multicenter, open-label, dose-escalating study will assess the safety, tolerability, and pharmacokinetics of DMOT4039A in participants with unresectable pancreatic or platinum-resistant ovarian cancer. Cohorts of participants will receive multiple ascending intravenous doses of DMOT4039A.
Interventions
- DRUG DMOT4039A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2011-11 |
| Est. Completion | 2015-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01469793
The ClinicalTrials.gov registry entry for NCT01469793 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 71 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DMOT4039A is the first listed.
NCT01469793 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01469793 about?
NCT01469793 is a clinical study titled "A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer". This multicenter, open-label, dose-escalating study will assess the safety, tolerability, and pharmacokinetics of DMOT4039A in participants with unresectable pancreatic or platinum-resistant ovarian cancer. Cohorts of participants will receive multiple ascending intravenous doses of DMOT4039A.
What is the current status of trial NCT01469793?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 71 participants. The study started on 2011-11. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01469793?
The interventions under investigation include: DMOT4039A (DRUG).
Who is sponsoring clinical trial NCT01469793?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.